15 related articles for article (PubMed ID: 38677007)
1. Anticancer activities of epigallocatechin-3-gallate against cholangiocarcinoma cells.
Kwak TW; Park SB; Kim HJ; Jeong YI; Kang DH
Onco Targets Ther; 2017; 10():137-144. PubMed ID: 28053547
[TBL] [Abstract][Full Text] [Related]
2. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro.
Jin J; Chang Y; Wei W; He YF; Hu SS; Wang D; Wu YJ
Acta Pharmacol Sin; 2012 May; 33(5):701-9. PubMed ID: 22555372
[TBL] [Abstract][Full Text] [Related]
3. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
4. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.
Zapf MA; Kothari AN; Weber CE; Arffa ML; Wai PY; Driver J; Gupta GN; Kuo PC; Mi Z
Surgery; 2015 Oct; 158(4):1039-47; discussion 1047-8. PubMed ID: 26189955
[TBL] [Abstract][Full Text] [Related]
5. Synergetic Effect of EP1 Receptor Antagonist and (-)-Epigallocatechin-3-gallate in Hepatocellular Carcinoma.
Yang H; Wang M; Sun H; Zhu S; Jin J
Pharmacology; 2019; 104(5-6):267-275. PubMed ID: 31434088
[TBL] [Abstract][Full Text] [Related]
6. The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Zhou H; Fu LX; Li L; Chen YY; Zhu HQ; Zhou JL; Lv MX; Gan RZ; Zhang XX; Liang G
J Ethnopharmacol; 2020 Oct; 261():113118. PubMed ID: 32621953
[TBL] [Abstract][Full Text] [Related]
7. Investigation of folate-modified EGCG-loaded thermosensitive nanospheres inducing immunogenic cell death and damage-associated molecular patterns in hepatocellular carcinoma.
He L; Peng L; Wang L; Jiang X; Sun X; Li H; Lin T; Wu Z; Lin S
Biochem Biophys Res Commun; 2024 Jun; 714():149976. PubMed ID: 38677007
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]